{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:07:29Z","timestamp":1791230849325,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.ijpharm.2011.11.008","type":"journal-article","created":{"date-parts":[[2011,11,11]],"date-time":"2011-11-11T04:28:24Z","timestamp":1320985704000},"page":"264-270","source":"Crossref","is-referenced-by-count":14,"title":["Targeted diazeniumdiolates: Localized nitric oxide release from glioma-specific peptides and proteins"],"prefix":"10.1016","volume":"422","author":[{"given":"Shahana","family":"Safdar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakeshia J.","family":"Taite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2011.11.008_bib0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1517\/14712598.1.2.239","article-title":"Gene therapy for high grade gliomas","volume":"1","author":"Alavi","year":"2001","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0010","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/74710","article-title":"Gene therapy of experimental brain tumors using neural progenitor cells","volume":"6","author":"Benedetti","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0015","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0142-9612(00)00153-8","article-title":"Nitric oxide-generating polymers reduce platelet adhesion and smooth muscle cell proliferation","volume":"21","author":"Bohl","year":"2000","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0020","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/smll.200700784","article-title":"In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes","volume":"4","author":"Conroy","year":"2008","journal-title":"Small"},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0025","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1021\/ja002899q","article-title":"Chemistry of the diazeniumdiolates. 2. Kinetics and mechanism of dissociation to nitric oxide in aqueous solution","volume":"123","author":"Davies","year":"2001","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0030","doi-asserted-by":"crossref","first-page":"C361","DOI":"10.1152\/ajpcell.1993.264.2.C361","article-title":"Purification and characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion","volume":"264","author":"DeBin","year":"1993","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0035","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1074\/jbc.M205662200","article-title":"Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2","volume":"278","author":"Deshane","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0040","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1021\/ic0349609","article-title":"The mechanism of NO formation from the decomposition of dialkylamino diazeniumdiolates: density functional theory and CBS-QB3 predictions","volume":"43","author":"Dutton","year":"2004","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0045","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrc1910","article-title":"The role of nitric oxide in tumour progression","volume":"6","author":"Fukumura","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0050","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.neuropharm.2009.12.019","article-title":"Primary brain tumors, neural stem cell, and brain tumor cancer cells: where is the link?","volume":"58","author":"Germano","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0055","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/carcin\/17.11.2501","article-title":"Nitric oxide inhibits DNA ligase activity: potential mechanisms for NO-mediated DNA damage","volume":"17","author":"Graziewicz","year":"1996","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0060","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.30.9.907","article-title":"Assumptions in the radiotherapy of glioblastoma","volume":"30","author":"Hochberg","year":"1980","journal-title":"Neurology"},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0065","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1021\/jo00058a030","article-title":"New nitric oxide-releasing zwitterions derived from polyamines","volume":"58","author":"Hrabie","year":"1993","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0070","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1021\/bc990035s","article-title":"Conversion of proteins to diazeniumdiolate-based nitric oxide donors","volume":"10","author":"Hrabie","year":"1999","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/hh0102.102330","article-title":"Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview","volume":"90","author":"Ignarro","year":"2002","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0080","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1021\/bm049419y","article-title":"Nitric oxide-producing polyurethanes","volume":"6","author":"Jun","year":"2005","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0085","series-title":"Cardiovascular & Hematological Agents in Medicinal Chemistry","article-title":"Development of nitric oxide donors for the treatment of cardiovascular diseases","author":"Katsumi","year":"2007"},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0090","series-title":"Methods in Enzymology","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0076-6879(96)68030-6","article-title":"\u201cNONOates\u201d (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms","author":"Keefer","year":"1996"},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1023\/A:1006160305294","article-title":"Growth inhibition and radiosensitization of cultured glioma cells by nitric oxide generating agents","volume":"42","author":"Kurimoto","year":"1999","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0100","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.neuint.2006.07.001","article-title":"Malignant glioma progression and nitric oxide","volume":"49","author":"Lam-Himlin","year":"2006","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0105","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bjp.0707224","article-title":"Recent developments in nitric oxide donor drugs","volume":"151","author":"Miller","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0110","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1016\/S0021-9258(18)94488-1","article-title":"Amino acid analysis: aqueous dimethyl sulfoxide as solvent for the ninhydrin reaction","volume":"243","author":"Moore","year":"1968","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0115","doi-asserted-by":"crossref","first-page":"G1313","DOI":"10.1152\/ajpgi.1999.276.6.G1313","article-title":"Therapeutic potential of nitric oxide donors and inhibitors","volume":"276","author":"Muscara","year":"1999","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0120","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s00018-007-6342-5","article-title":"Molecular targets of glioma invasion","volume":"64","author":"Nakada","year":"2007","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0125","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0130","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.addr.2005.09.014","article-title":"Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex","volume":"57","author":"Patri","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0135","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ymthe.2005.07.357","article-title":"Gene therapy for malignant glioma: current clinical status","volume":"12","author":"Pulkkanen","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0140","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/BF02951428","article-title":"Therapeutic advances for glioblastoma multiforme: current status and future prospects","volume":"9","author":"Robins","year":"2007","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0145","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1021\/jm9701031","article-title":"Targeting nitric oxide (NO) delivery in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor-\u03b1-induced apoptosis and toxicity in the liver","volume":"40","author":"Saavedra","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0150","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/02688690120057628","article-title":"Nitric oxide and glioma: a target for novel therapy?","volume":"15","author":"Shinoda","year":"2001","journal-title":"Br. J. Neurosurg."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0155","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/cncr.22741","article-title":"Molecularly targeted therapy for malignant glioma","volume":"110","author":"Sathornsumetee","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0160","first-page":"4871","article-title":"Use of chlorotoxin for targeting of primary brain tumors","volume":"58","author":"Soroceanu","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0165","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0169-409X(99)00062-9","article-title":"Targeted drug delivery via the folate receptor","volume":"41","author":"Sudimack","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0170","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/jo00107a024","article-title":"Toward the generation of NO in biological systems theoretical studies of the N2O2 grouping","volume":"60","author":"Taylor","year":"1995","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0175","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/smll.200800646","article-title":"Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles","volume":"5","author":"Veiseh","year":"2009","journal-title":"Small"},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0180","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.1158\/0008-5472.CAN-09-1157","article-title":"Specific targeting of brain tumors with an optical\/magnetic resonance imaging nanoprobe across the blood\u2013brain barrier","volume":"69","author":"Veiseh","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0185","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1021\/cr000040l","article-title":"Nitric oxide donors: chemical activities and biological applications","volume":"102","author":"Wang","year":"2002","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0190","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3171\/2008.6.17607","article-title":"Growth inhibition and chemosensitization of exogenous nitric oxide released from NONOates in glioma cells in vitro","volume":"110","author":"Weyerbrock","year":"2009","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0195","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jconrel.2008.05.015","article-title":"A peptide-based carrier for intracellular delivery of proteins into malignant glial cells in vitro","volume":"130","author":"Wu","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0200","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.molmed.2008.03.003","article-title":"Cell- and peptide-based immunotherapeutic approaches for glioma","volume":"14","author":"Yamanaka","year":"2008","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0205","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1158\/1078-0432.CCR-07-1826","article-title":"Increase in brain tumor permeability in glioma-bearing rats with nitric oxide donors","volume":"14","author":"Yin","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijpharm.2011.11.008_bib0210","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.2741\/1492","article-title":"Real time and in vivo monitoring of nitric oxide by electrochemical sensors-from dream to reality","volume":"9","author":"Zhang","year":"2004","journal-title":"Front. Biosci."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517311010441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517311010441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T02:27:54Z","timestamp":1639621674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517311010441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":42,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0378517311010441"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2011.11.008","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}